FindTrial
Sign In

Selection of high risk group of gastric cancer development in patients eradicated Helicobacter pylori using expression level of gastric mucosal PSCA/CD44v9: Retrospective multi-center trial

Selection of high risk group of gastric cancer development in patients eradicated Helicobacter pylori using expression level of gastric mucosal PSCA/CD44v9: Retrospective multi-center trial - Selection of high risk group of gastric cancer development

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000022898
Enrollment
1000
Registered
2016-06-28
Start date
2016-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

None listed

Sponsors

Shiga University of Medical Science Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Early stage gastric cancer patients treated with endoscopic resection from Apr 2006 to Mar 2016 and were followed. 2. To check H. pylori infection by urea breath test, rapid urease test, culture or/and IgG. 3. With gastric cancer or adenoma pathologically 4. To be stocked resected gastric cancer. 5. With informed consent to enroll in this study

Exclusion criteria

Exclusion criteria: 1. Patients who cannot check metachronou gastric cancer routinely. 2. patients received chemotherapy 3. with mental disorder

Design outcomes

Primary

MeasureTime frame
Observation period from endoscopic resection early stage gastric cancer to development of metachronous gastric cancer in early-stage gastric cancer patients eradicated with H. pylori infection—

Countries

Japan

Contacts

Public ContactMitsushige Sugimoto

Shiga University of Medical Science Hospital Division of Digestive Endoscopy

sugimo@belle.shiga-med.ac.jp077-548-2618

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026